Healthcare company-building profile
Mayo Clinic Department of Business Development (including Mayo Clinic Ventures)
Mayo Clinic
Source-based profile
Program at a Glance
- Program type
- Accelerator
- Program category
- Health system accelerator
- Organization
- Mayo Clinic
- Organization type
- Hospital or health system
- Location
- Rochester, Minnesota
- Company stage served
- Early stage to Growth stage
- Cohort or participation model
- Not publicly documented
- Investment or funding offered
- Not publicly documented
- Published investment terms
- Not publicly documented
- Equity or fee model
- Not publicly documented
- Clinical or hospital connection
- Yes
- Application status
- Active
Public description
About the program
The Mayo Clinic Department of Business Development is the institution's official front door for technology commercialization, startup formation, equity investment, and strategic partnerships. It operates two divisions, Mayo Clinic Ventures and Corporate Development, which work together to license Mayo intellectual property, form and spin out companies, run a business accelerator for early-stage ventures, and participate in venture and growth-stage funding rounds. Commercialization pathways span licensing, spinouts, direct equity investment, strategic partnerships, joint ventures, and acquisitions across clinical, therapeutic, diagnostic, digital health, and medical device categories. Outside companies engage by licensing Mayo technology, entering co-development or knowledge-content agreements, taking investment from Mayo Clinic Ventures, or forming joint ventures with the clinic.
What the program publicly emphasizes
Focus areas and features
- Category: Health system accelerator
Publicly documented people and network
Program leadership and alumni
- Program leader
- Andrew J. Danielsen — Chief Business Development Officer (Peter A. Noseworthy, M.D., serves as Medical Director)
- Notable alumni named in public materials
- 440+ startups built on or using Mayo Clinic technology as of 2025; more than $400 million in investment capital deployed for strategic collaborations and equity investments; more than $1.3 billion returned to Mayo Clinic from inception through 2025 to support practice, education, and research; commercialization routes include licensing, spinouts, investment, strategic partnerships, joint ventures, and acquisitions
Sources
External source links open in a new tab.